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ABSTRACT
Objective: Limited data exist concerning the role of
inhaled hypertonic saline (HS) in decreasing
pulmonary exacerbations in cystic ﬁbrosis (CF),
especially as more advanced stages of CF lung disease
were excluded in prior studies. Herein, the authors
retrospectively determined the efﬁcacy of inhaled HS in
reducing CF pulmonary exacerbations when stratiﬁed
according to the severity of CF lung disease.
Stratiﬁcation was based on the framework of the
Pulmonary Therapeutics Committee’s published
gradation of obstructive lung physiology in CF, that is,
mild (FEV1 >70%), moderate (FEV1 40e70%) and
severe (FEV1 <40%) lung disease, respectively.
Design: A retrospective review of the Port CF database
over a 3-year period performed at an academic CF care
centre.
Results: 340 pulmonary exacerbations were identiﬁed;
inhaled HS was being used in 99 of these cases.
Univariate analysis demonstrated a signiﬁcant
reduction in pulmonary exacerbations only in mild
obstruction (OR¼0.09, CI 0.01 to 0.81, p¼0.012);
however, multivariate logistic regression that adjusted
for confounding variables showed a reduction in
pulmonary exacerbations across the entire spectrum
of obstructive lung disease when using inhaled HS,
that is, mild obstructive CF lung disease (OR¼0.17, CI
0.05 to 0.58, p¼0.004), moderate obstructive CF lung
disease (OR¼0.39, CI 0.16 to 0.93, p¼0.034), as well
as severe obstructive CF lung disease (OR¼0.02,
CI 0.001 to 0.45, p¼0.015). Moreover, inhaled HS
appeared reasonably well tolerated across all stages of
lung-disease severity, and was discontinued in only
7% of cases (n¼4) with severe lung disease.
Conclusion: In this study, inhaled HS appeared to
reduce pulmonary exacerbations in CF lung disease at
all stages of obstruction. This underscores the
importance of therapeutic inhaled HS in CF lung
disease, regardless of the severity of lung obstruction.
INTRODUCTION
Cystic ﬁbrosis (CF) is characterised by
decreased clearance of airway mucus that
over time leads to progressive inﬂammatory
loss of lung function consequent to infectious
exacerbations.
1 In this context, the landmark
trial of Elkins and colleagues
2 established
that inhaled hypertonic 7% saline (HS)
nebulised twice daily in CF lung disease
improved the overall forced expiratory
volume in 1 s (FEV1) and the forced vital
capacity (FVC) by 68 ml and 82 ml, respec-
tively, although it did not appreciably alter
the rate of decline of FEV1. The effect of
inhaled HS in decreasing the frequency of
clinical exacerbations of CF lung disease was
reported as a secondary outcome in this trial;
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ARTICLE SUMMARY
Article focus
- Prior studies have demonstrated that inhaled
hypertonic saline (HS) improves the forced
expiratory volume in 1 s (FEV1) and the forced
vital capacity (FVC) in patients with cystic
ﬁbrosis.
- Inhaled HS also decreases the frequency of
pulmonary exacerbations in cystic ﬁbrosis; this
aspect has been less extensively studied, espe-
cially in more severe forms of disease.
- This study focuses on the role of inhaled HS in
decreasing the frequency of pulmonary exacer-
bations in patients stratiﬁed according to the
severity of CF lung disease.
Key messages
- This study suggests that inhaled HS may be
beneﬁcial in reducing pulmonary exacerbations
at all stages of CF lung disease severity, thus
highlighting the importance of inhaled HS as
a key component of the CF therapeutic arma-
mentarium.
- The observed beneﬁt of inhaled HS appeared in
addition to that of established airway clearance
strategies such as nebulised rhDNase therapy
and mechanical airway clearance devices.
- This study found no indication of any excessive
discontinuation of inhaled HS due to cough or
bronchospasm in more severe forms of CF lung
disease, suggesting that it is reasonably well
tolerated even in such cases.
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Open Access Researcha 56% relative reduction in exacerbations for the HS-
treated group.
2 Prior to this report, other trials had
likewise demonstrated the short-term beneﬁt of HS,
34
but had not speciﬁcally addressed the effect of inhaled
HS in decreasing pulmonary exacerbations in CF lung
disease. We sought to better deﬁne the therapeutic role
of inhaled HS in reducing the frequency of pulmonary
exacerbations based on the severity of underlying CF
lung disease; this is in accordance with the current
stratiﬁed framework of evidence-based Cystic Fibrosis
Pulmonary Guidelines.
5 The original abstract of this
study was presented at the 2009 annual scientiﬁc meeting
of the American College of Chest Physicians.
6
METHODS
A retrospective assessment of the Saint Louis University
(SLU) institutional data within the Port CF database
registry was performed. The SLU CF care centre is
a combined adult and paediatric academic accredited CF
centre. The Port CF registry captures both clinical and
epidemiological data from all CF patient during each
individual visit to the CF care centre, and is recorded as
per an established nationwide protocol. Approval was
obtained from the Institutional Review Board at SLU. We
initially identiﬁed a cohort of CF patients who presented
over a 3-year period beginning January 2006, corre-
sponding to the publication of the Elkins study.
2 All
episodes of pulmonary exacerbations necessitating
either hospitalisation or treatment with home intrave-
nous antibiotics were identiﬁed. Other recorded vari-
ables included utilisation of inhaled HS, airway-
clearance methodologies, demographics, sputum
culture results and spirometric indices. Groups were
compared utilising c
2 and independent t testing for
categorical and continuous variables, respectively. The
severity of CF lung disease was further stratiﬁed into
three groups based on the framework of the Pulmonary
Therapeutics Committee’s published gradation of
obstructive lung physiology in CF,
5 that is, mild (FEV1
>70% predicted), moderate (FEV1 40e70% predicted)
and severe (FEV1 <40% predicted) lung disease,
respectively. A univariate c
2 analysis was performed
separately in all three subgroups to assess the effects of
HS in reducing the frequency of pulmonary exacerba-
tions; consequently, a p value of 0.016 was considered
signiﬁcant utilising a Bonferroni adjustment for multiple
comparisons. Finally, a logistic regression was also
performed in all subgroups to adjust for differences in
subgroup characteristics such as age, gender, BMI,
inhaled HS, sputum positivity for MRSA or Pseudomonas,
as well as the spirometric FEV1 and FVC. A statistical
analysis was performed using SPSS V.17.
RESULTS
Overall, 340 pulmonary exacerbations were identiﬁed
from a cohort of 424 patients. The average age of the
entire cohort was 31611 years, and 55% were male.
Inhaled HS was being used in 99/340 cases with exac-
erbations (29%). Fifty patients (12%), 183 patients
(45%) and 170 patients (42%) of the cohort were cate-
gorised as having mild, moderate and severe CF lung
disease, respectively; 21 patients were uncategorised
secondary to unclear documentation of the FEV1.
Demographic and clinical variables are summarised in
table 1. Using a univariate analysis, we found a signiﬁ-
cant reduction in pulmonary exacerbations in the
subgroup of patients using HS with mild lung disease
(OR¼0.09, CI 0.01 to 0.81, p¼0.012), whereas no
reductions were found in the cohort of subjects with
moderate (OR¼1.33, CI 0.65 to 2.74, p¼0.432) and
severe lung disease (OR¼5.62, CI 0.73 to 43.21,
p¼0.063). However, a subsequent multivariate analysis
using logistic regression modelling demonstrated
a reduction in pulmonary exacerbations when using HS
at all stages of obstruction, that is, mild obstructive CF
lung disease (OR¼0.17, CI 0.05 to 0.58, p¼0.004),
moderate obstructive CF lung disease (OR¼0.39, CI 0.16
to 0.93, p¼0.034), as well as severe obstructive CF lung
disease (OR¼0.02, CI 0.001 to 0.45, p¼0.015). These
ﬁndings are summarised in tables 2, 3, with individual
regression tables in the supplementary appendix. Addi-
tionally, inhaled HS was discontinued in only four cases
(7%) with severe lung disease.
DISCUSSION
Exacerbations of CF lung disease account for appre-
ciable morbidity and burden of this disease, which
collectively greatly decrease physical functioning and
psychosocial quality of life.
7 Pulmonary exacerbations in
particular signiﬁcantly contribute to the overall cost of
CF care, accounting for up to 47% of overall costs in one
study.
8 Accordingly, measures to decrease pulmonary
exacerbations are important. Inhaled HS decreases the
viscosity of pulmonary secretions and thereby improves
the rheological properties of mucus secondary to
hydration of the airway surface.
9 In addition, HS
osmotically induces a sustained increase in the airway
surface liquid volume depth, possibly allowing the cilia
ARTICLE SUMMARY
Strengths and limitations of this study
- This study establishes the role of inhaled HS in reducing the
number of pulmonary exacerbations at more advanced stages
of CF lung disease severity, which is of special signiﬁcance
considering that the more severe forms of CF lung disease had
been excluded in previous studies.
- Our study group had a signiﬁcantly higher usage of nebulised
rhDNase (100%) and other mechanical airway clearance
therapies (97%) compared with previous studies, thus
supporting the additional beneﬁcial effect of inhaled HS.
- Our two study groups had differences in epidemiological
characteristics, potentially introducing bias into the results. We
have attempted to minimise for this by performing a logistic
regression; however, we acknowledge the inherent limitations
of such a retrospective study design.
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Inhaled hypertonic saline in CF lung diseaseto beat freely by recoupling the mucociliary mecha-
nism.
10 Inhaled HS for CF lung disease is currently
assigned a Grade II recommendation in the Cystic
Fibrosis Pulmonary Guidelines published in 2007,
5
based on evidence from the above-cited trials.
2e4
Notably, in the trial reporting the efﬁcacy of HS in
reducing clinical exacerbations,
2 patients with severe
CF lung disease (as classiﬁed by FEV1 <40% predicted)
were excluded; moreover, only approximately one-third
of the included participants were using nebulised
rhDNase.
Here, we have assessed the effects of inhaled HS in
reducing the number of pulmonary exacerbations across
varying levels of lung disease severity, especially consid-
ering that more severe forms of CF lung disease had
been previously excluded.
2 Our study suggests that
inhaled HS is beneﬁcial in reducing exacerbations across
all stages of CF lung disease using multivariate analyses,
even though the univariate analysis only showed beneﬁt
in mild CF lung disease. These ﬁndings underscore the
potential therapeutic beneﬁt of initiating inhaled HS at
any stage in the disease continuum. Our study group had
a signiﬁcantly higher usage of nebulised rhDNase
(100%) and other mechanical airway clearance therapies
(97%) compared with previous studies.
2 Hence, we
postulate that there may be an additional beneﬁt of
inhaled HS in patients who are already on established
airway-clearance strategies. We also found no indication
of any excessive discontinuation of inhaled HS due to
cough or bronchospasm in more severe forms of CF lung
disease, suggesting that it is reasonably well tolerated
even in such cases.
Even so, the methodological limitations of our study
must be acknowledged, principally its retrospective
nature and lack of randomisation. Mild exacerbations
could possibly go unreported; moreover, there was no
uniform protocol in place to assess compliance with
therapy. Furthermore, the two study groups had differ-
ences in epidemiological characteristics, for example,
the lower proportion of sputum Pseudomonas positivity in
HS users, thereby potentially lending bias to our inter-
pretation. In this context, regression analyses in an
attempt to adjust for these variable clinical and epide-
miological characteristics were performed. However,
ultimately, prospective randomised controlled studies
with larger numbers of included participants are
warranted to better assess the beneﬁt of inhaled HS at
varying stages of CF lung-disease severity.
CONCLUSION
Our study demonstrated that pulmonary exacerbations
appear to be reduced in patients with CF lung disease of
any severity during active use of inhaled HS. The bene-
ﬁcial effect of HS was additive to other airway-clearance
measures such as nebulised rhDNase and mechanical
clearance strategies. Moreover, inhaled HS appeared
reasonably well tolerated. Recently, the effectiveness of
alternative therapies such as nebulised mannitol for
mucociliary clearance has been reported.
11 Until these
newer strategies are better established, we support the
Table 1 Baseline epidemiological characteristics between hypertonic-saline-treated and non-treated groups
Hypertonic
saline (n[121)
No hypertonic
saline (n[303) p Value
Age, mean6SD 33610 31612 0.13
Male gender, n (%) 37 (31%) 196 (65%) <0.001
Body mass index, mean6SD 20.860.7 21.965.7 0.001
Forced expiratory volume in 1 s (% predicted), mean6SD 50612 46623 0.016
Forced vital capacity (% predicted), mean6SD 73695 7 624 <0.001
Use of recombinant human DNase, n (%) 121 (100%) 303 (100%) NA
Sputum positivity for Pseudomonas aeruginosa, n (%) 60 (50%) 211 (70%) <0.001
Sputum positivity for methicillin-resistant Staphylococcus
aureus, n (%)
60 (50%) 97 (32%) 0.001
Airway-clearance device (chest vest or ﬂutter valve), n (%) 80 (93%) 143 (97%)
Hospitalisation/home intravenous antibiotics, n (%) 41 (52%)/41 (48%) 88 (60%)/60 (40%)
Table 2 ORs using inhaled hypertonic saline (n¼99) for
pulmonary exacerbations (n¼340) using a univariate
analysis
Lung-disease
severity OR
CIs
p Value Lower Higher
Mild (n¼50) 0.09 0.01 0.812 0.012
Moderate (n¼183) 1.33 0.65 2.74 0.432
Severe (n¼170) 5.62 0.73 43.21 0.063
Numbers in bold indicate statistical signiﬁcance.
Table 3 ORs using inhaled hypertonic saline (n¼99) for
pulmonary exacerbations (n¼340) using a multivariate
analysis
Lung-disease
severity OR
CIs
p Value Lower Higher
Mild (n¼50) 0.17 0.05 0.58 0.004
Moderate (n¼183) 0.39 0.16 0.93 0.034
Severe (n¼170) 0.02 0.001 0.452 0.015
Dmello D, Nayak RP, Matuschak GM. BMJ Open 2011;1:e000019. doi:10.1136/bmjopen-2010-000019 3
Inhaled hypertonic saline in CF lung diseaseuse of inhaled HS in CF lung disease, in the context of
reducing pulmonary exacerbations. This is especially so
given the potential to improve lung function, quality of
life, CF-related costs and possibly mortality.
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